logo
Plus   Neg
Share
Email
Comment

AstraZeneca Begins Olaparib Phase III Trial; Reverses $285 Mln Charge

AstraZeneca PLC (AZN.L,AZN) Wednesday said it enrolled the first patient in the Phase III SOLO, or Study of OLaparib in Ovarian cancer, programme. Olaparib, an innovative oral poly ADP ribose polymerase inhibitor is being investigated for the treatment of BRCA mutated ovarian cancer in SOLO. The clinical development is designed to study the benefit, progression free survival, of olaparib as a maintenance monotherapy in BRCA mutated ovarian cancer patients who are in complete or partial response following platinum-based chemotherapy in the first line setting, SOLO 1, and relapsed setting, SOLO 2.

A pre-tax impairment charge of $285 million, which was incurred in December 2011 after deciding not to progress olaparib into phase III, will be reversed in the third quarter of 2013, following the start of the programme. This reversal will be excluded from the core earning per share, the company said.

The SOLO 1 study is being conducted in collaboration with the Gynecologic Oncology Group and the SOLO 2 study with the European Network of Gynaecological Oncological Trial Groups. Both trials are randomised, double blind, placebo controlled studies that utilise the tablet formulation of olaparib at a dose of 300mg twice daily.

Separately, Myriad Genetics, Inc. (MYGN) said it is expanding its collaboration agreement with AstraZeneca to provide companion diagnostics for the olaparib Phase 3 clinical development program. Pursuant to the agreement, Myriad will build out a new laboratory within its Salt Lake City facility in accordance with U.S. Food and Drug Administration regulations for companion diagnostic devices.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Citigroup Inc. on Tuesday reported a loss for the fourth quarter, reflecting the impact of a non-cash charge of $22 billion due to the recent U.S. tax reform that more than offset an increase in revenues. However, adjusted earnings per share for the quarter beat analysts' estimates, while revenues were in line with expectations. Shares of BP Plc were losing around 2 percent in the morning trading in London after the British energy giant said Tuesday that it now expects to take a post-tax non-operating charge of around $1.7 billion in its fourth quarter for Deepwater Horizon settlement program. BlackBerry Ltd. has introduced a new a cloud-based cybersecurity program that will scan automakers' software for threats amid increased concerns about hacking in Internet-connected cars. BlackBerry Jarvis, the transformational software cybersecurity product, helps carmakers detect security flaws in software before it goes into their vehicles.
comments powered by Disqus
Follow RTT